Age (median, range) | 66 (45-88) | Â |
---|---|---|
 | n | % |
Number of extracerebral metastatic sites at occurrence of BM | Â | Â |
   - 1 | 7 | 58.3 |
   - 2 | 2 | 16.7 |
   - ≥ 3 |  |  |
Location of extracerebral metastases | Â | Â |
Lung | 8 | 66.7 |
Liver | 2 | 16.7 |
Bone | 2 | 16.7 |
LN | 3 | 25 |
other | 5 | 41.7 |
Time from primary tumor to occurrence of BM | Â | Â |
< 2 years | 9 | 75 |
> 2 years | 3 | 25 |
Number of brain lesions | Â | Â |
1 | 6 | 50 |
2 | 4 | 33.3 |
> 2 | 2 | 16.7 |
Location of BM metastases | Â | Â |
   - frontal | 4 | 33.3 |
   - parietal | 2 | 16.7 |
   - cerebellar | 4 | 33.3 |
   - temporal | 1 | 8.3 |
   - dissiminated | 1 | 8.3 |
Lesion size | Â | Â |
1cm | 1 | 8.3 |
1-2cm | 2 | 16.7 |
> 2cm | 9 | 75 |
CNS symptoms | Â | Â |
Yes | 10 | 83.3 |
No | 2 | 16.7 |
   - psychiatric | 1 | 8.3 |
   - vertigo | 2 | 16.7 |
   - headache | 5 | 41.7 |
   - ataxia | 3 | 25 |
   - hemiplegia | 1 | 8.3 |
Local treatment for BM | Â | Â |
   - surgery | 2 | 16.7 |
   - surgery+ SR | 1 | 8.3 |
   - surgery+WBRT | 2 | 16.7 |
   - SR | 2 | 16.7 |
   - SR+WBRT | 2 | 16.7 |
   - WBRT | 3 | 25 |
First targeted agent after local control of BM | Â | Â |
   - Bevacizumab | 2 | 16.7 |
   - Sunitinib | 7 | 58.3 |
   - Sorafenib | 2 | 16.7 |
   - Temsirolimus | 1 | 8.3 |